118 results about "Postmenopausal osteoporosis" patented technology

The invention discloses antibodies that bind high specificity to human RANKL (Receptor Activator for Nuclear Factor kappa B Ligand), wherein, the antibodies are used for the treatment of bone erosion caused by astogeny, hormonotherapy, postmenopausal osteoporosis, bone metastasis, and inflammation. The invention also discloses DNA sequences and supposed amino acid sequences of the antibodies.

The invention belongs to the technical field of traditional Chinese medicines and relates to a traditional Chinese medicine composition for treating female postmenopausal osteoporosis and a preparation method thereof. In order to overcome the defects in the prior art, the invention provides the traditional Chinese medicine composition which can increase the bone mineral density of a patient suffering from postmenopausal osteoporosis and relieve secondary pain and inflammatory reaction, caused by the postmenopausal osteoporosis. The traditional Chinese medicine composition is mainly prepared from the following raw materials: palmleaf raspberry fruit, atractylodes macrocephala, radix paeoniae alba, tuber fleeceflower root, spina date seed, radix angelicae sinensis, radix codonopsis, radix morindae officinalis, radix acanthopanacis senticosi, rhizoma dioscoreae, poria cocos, radix rehmanniae preparata, radix puerariae, eucommia bark, herba menthae, rhizoma polygonati, fructus ligustri lucidi, epimedium herb, fructus lycii, fructus corni, calcium lactate, semen cuscutae, bovine bone powder, fortune's drynaria rhizome and radix glycyrrhizae. Pharmacological experiments and clinical trials prove that the traditional Chinese medicine composition has a significant effect for treating postmenopausal osteoporosis, so that the traditional Chinese medicine composition has a wide promotion value in the medical field.

The invention provides a miRNA (micro Ribonucleic Acid) marker and a kit related to postmenopausal osteoporosis and particularly relates to application of a miR-338 cluster as a postmenopausal osteoporosis marker. According to the invention, high expression of the miR-338 cluster such as miR-338-3p and / or miR-3065-5p in postmenopausal osteoporosis patients is found; the miR-338 cluster can be used as a marker for the postmenopausal osteoporosis and is used for preparing an auxiliary diagnosis kit for the postmenopausal osteoporosis; the auxiliary diagnosis kit can be used for specifically detecting the expression quantity of the miR-338 cluster in tissues and is early and effectively used for early auxiliary diagnosis of clinical postmenopausal osteoporosis without noninvasive. Besides, an inhibitor of the miR-338 cluster has the efficacy of promoting osteogenesis, so that the postmenopausal osteoporosis is effectively treated or prevented.

The invention discloses a traditional Chinese medical composition for treating postmenopausal osteoporosis and belongs to traditional Chinese medical compositions. The traditional Chinese medical composition for treating postmenopausal osteoporosis comprises herba epimedii, rhizoma cibotii, rhizoma curculiginis, cistanche, Semen Cuscutae, flatstem milkvetch seed, glossy privet fruit, Poria cocos, radix paeoniae alba, radix bupleuri, cassia twig, hairyvein agrimony, the fruit of Chinese wolfberry, dogwood, fried Rhizoma Atractylodis Macrocephalae, Caulis Spatholobi, loranthus parasiticus, prepared fleece flower root, Angelica sinensis and honey-fried licorice root in a certain weight proportion. The traditional Chinese medical composition for treating postmenopausal osteoporosis has the effects of facilitating liver and tonifying kidneys and strengthening tendons and bones, and can be used to effectively treat postmenopausal osteoporosis.

The invention provides a traditional Chinese medicine composition for treating postmenopausal osteoporosis. The traditional Chinese medicine composition comprises medicinal cyathula root, morinda officinalis, drynaria rhizome, cuscuta chinensis, walnut kernel, tortoise shell, herba epimedii, parasitic loranthus, cortex acanthopanacis, fructus ligustri lucidi, hematoxylon, bighead atractylodes rhizome, prepared rehmannia root and ligusticum wallichii. After being adopted for treating postmenopausal osteoporosis, the traditional Chinese medicine composition has the advantages that the side effect is small, the curative effect is good, the cost is low, the cure rate is high, the drug resistance is avoided, the taking is convenient, and the like.

The invention relates to a medicine combination for preventing and treating the osteoporosis, specifically a medicine produced by epimedium, bark of eucommia, fructus psoraleae, himalayan teasel root, astragalus root, native copper, chaff flower root and mongolian snakegourd root and the producing method thereof, which is suitable for preventing and treating constitutional osteoporosis including osteoporosis after menostasia and age-related osteoporosis and the fracture generated by constitutional osteoporosis.

The invention discloses an extraction method and the application of an urogenic stem cell exosome. The extraction method comprises the following specific steps: firstly, collecting urine, then carrying out first-time centrifugation, and adding PBS into a first residual liquid obtained after supernatant is removed; carrying out second-time centrifugation, resuspending the second-time residual liquid obtained after the supernatant is removed through a primary culture medium to obtain urogenic stem cell suspension solution; secondly, carrying out multiplication culture on the urogenic stem cellsand passing down to the second to the sixth generation for later use; thirdly, changing the culture medium obtained in the second step, then continuously culturing, collecting and culturing supernatant, centrifuging, filtering and carrying out centrifugal concentration; adding an exosome extraction reagent for extracting to obtain a resuspension solution of the urogenic stem cells. The urogenic stem cell exosome extracted by the invention is proved by animal experiments to have the advantages of good therapeutic effects on senile osteoporosis, postmenopausal osteoporosis and disuse osteoporosis.

The invention relates to traditional Chinese medicine compound extract for treating postmenopausal osteoporosis. The traditional Chinese medicine compound extract for treating postmenopausal osteoporosis is prepared from eleven traditional Chinese medicines of patrinia villosa juss., densefruit pittany root-bark, hairyvein agrimony, radix bupleuri, common cnidium fruit, rhodiola rosea, cassia seed, semen platycladi, wild buckwheat, oriental waterplantain rhizome and licorice. The traditional Chinese medicine compound extract for treating postmenopausal osteoporosis is prepared through a carbon dioxide supercritical extraction technology and a macroporous absorption resin enrichment technology according to certain technological parameters. The traditional Chinese medicine compound extract has obvious effects of treating postmenopausal osteoporosis, and can be safely utilized for preparation of drug preparations and health-care foods, wherein the drug preparations and health-care foods have postmenopausal osteoporosis treatment effects.

The invention relates to a medicine for treating postmenopausal osteoporosis. The medicine is prepared from the following raw material medicines in parts by weight: 15 parts of Semen Cuscutae, 12 parts of Semen Euryales, 25 parts of medicated leaven, 10 parts of drynaria rhizome, 7 parts of Caulis Spatholobi, 8 parts of Sargent gloryvine, 10 parts of fructus liquidambaris, 12 parts of elderberry, 6 parts of immature tangerine and 5 parts of radix curcumae. The Semen Cuscutae, the Semen Euryales and the medicated leaven have the functions of nourishing liver and kidney and strengthening the spleen and stomach; the drynaria rhizome has the functions of strengthening tendons and bones to treat the root problem; the Caulis Spatholobi, the Sargent gloryvine and the elderberry have the functions of nourishing blood, activating blood and stopping pain; the fructus liquidambaris has the functions of dispelling wind and activating collaterals; the immature tangerine and the chinaberry have the functions of soothing the liver, regulating vital energy and removing stagnation; the medicines are combined for use with the effects of tonifying kidney, strengthening bone, activating blood and stopping pain; and the postmenopausal osteoporosis can be effectively treated.

The invention discloses an application of miR-6802-3p to early diagnosis of postmenopausal osteoporosis. MiRNA with differential expression between a postmenopausal osteoporosis patient and a normal control is screened out by sequencing, then large sample QPCR experiments prove that content of miR-6802-3p in blood of the postmenopausal osteoporosis patient is substantially up-regulated definitely,so that miR-6802-3p can serve as a molecular marker for diagnosing postmenopausal osteoporosis to be used for developing products for diagnosing postmenopausal osteoporosis.

The invention discloses a traditional Chinese medicine composition for treating postmenopausal osteoporosis, belonging to the field of traditional Chinese medicines. For overcoming the shortcomings of the prior art, the invention provides a traditional Chinese medicine that can increase the bone mineral density of a postmenopausal osteoporosis patient and also can relieve secondary pain and inflammatory response caused by postmenopausal osteoporosis. The traditional Chinese medicine composition is prepared from the following raw materials: black false hellebore, ligusticum wallichii, radix paeoniae alba, polygonum multiflorum, radix angelicae, angelica sinensis, codonopsis pilosula, gynostemma pentaphylla, acanthopanax root, the root of red-rooted salvia, poria cocos, prepared rhizome of rehmannia, the root of kudzu vine, asarum, mentha haplocalyx, xanthium sibiricum, glossy privet fruit, herba epimedii, the fruit of Chinese wolfberry, dogwood, radices sileris, the seed of Chinese dodder, bovine-derived power, astragalus membranaceus and liquorice. Pharmacology experiments and clinical experiments prove that the traditional Chinese medicine composition has a remarkable effect for treating postmenopausal osteoporosis, so the traditional Chinese medicine composition has a wide medical promotional value.

The invention relates to application of deferoxamine mesylate, in particular to application of the deferoxamine mesylate in preparing medicaments for treating postmenopausal osteoporosis. The deferoxamine mesylate has low toxicity and safety and can greatly reduce the loss of postmenopausal bone mineral contents.

The invention relates to a traditional Chinese medicine composition for treating postmenopausal osteoporosis, a preparation method and an application thereof. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 6-15 parts of eucommia ulmoides, 5-10 parts of fructus rubi and 10-12 parts of semen cuscutae. The traditional Chinese medicine composition has the effects of tonifying liver and kidneys, strengthening bones and muscles, warming yang to reduce urination and delaying senescence, is capable of improving symptoms of soreness and weakness of waist and knees, dizziness, frequent urination and the like, and can be used for successfully treating postmenopausal osteoporosis.

The invention relates to the technical field of medicine, in particular to an application of novel psoralea corylifolia isoflavone in preparation of medicines for preventing or treating postmenopausalosteoporosis, and a structure of the novel psoralea corylifolia isoflavone is shown as a formula I. The invention provides the novel application of the novel psoralea corylifolia isoflavone, and alsoprovides a novel thought for preventing and treating postmenopausal osteoporosis.

The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine for treating postmenopausal osteoporosis. The traditional Chinese medicine is prepared from prepared rehmannia, rhizoma cibotii, herba epimedii, fructus psoraleae, oyster, yam, prepared fleece-flower root, eucommia bark, gastrodia elata, medlar, dogwood fruit pulp, radix achyranthis bidentatae, codonopsis pilosula, donkey-hide gelatin, black sesame, parasitic loranthus, glossy privet and schisandra chinensis. The traditional Chinese medicine is in accordance with the theory of traditional Chinese medicinal differentiation, and is combined with the fact that the occurrence of postmenopausal osteoporosis is related to kidney deficiency and spleen deficiency, wherein kidney deficiency is a main pathogenesis of postmenopausal osteoporosis. From the view of traditional Chinese medicine, kidney governs bones and belongs to water in five elements, liver governs tendons and belongs to wood in five elements, so that deficiency of spleen and kidney means the loss of water and wood, which causes that wood is nourished; and tendons and bones are not tonified to cause postmenopausal osteoporosis with the passing of time. Thus, postmenopausal osteoporosis is treated by tonifying spleen and nourishing liver kidney to achieve the fundamental treatment effects of treating both principal and secondary aspect of disease, and preventing relapse.

The invention discloses application of probiotics or outer membrane vesicles thereof to preparing medicines for preventing and treating osteoporosis. The probiotics is an Akk bacterium. The probioticsor the outer membrane vesicles of the probiotics can be used for increasing the bone volume fractions of distal-end cancellous bones of femurs, increasing the numbers of bone trabeculas and loweringthe separation of the bone trabeculas. The probiotics or the outer membrane vesicles of the probiotics can be used for preparing the medicines, food or healthcare products for preventing and treatingpostmenopausal osteoporosis. The application has the advantage that novel, safe and effective biotherapy directions can be provided to treating the osteoporosis and particularly the postmenopausal osteoporosis by the application.

The invention discloses a diagnosis and treatment marker for postmenopausal osteoporosis, and the marker is miRNA-3656. According to the invention, the miRNA-3656 is proved to be relevant to the occurrence and development of the postmenopausal osteoporosis through a QPCR (Quantitative Polymerase Chain Reaction); and meanwhile, the differentiation of osteoblasts is proved to be influenced by the miRNA-3656 through cell experiments, indicating that the miRNA-3656 can be taken as a molecular target to be applied to early diagnosis and treatment of the postmenopausal osteoporosis.

The invention discloses a traditional Chinese medicine preparation for postmenopausal osteoporosis. Raw materials of the traditional Chinese medicine preparation comprise eucommia ulmoides, prepared rehmannia roots, epimedium brevicornum maxim, drynaria fortunei, cnidium monnieri, astragalus membranaceus, cuscuta chinensis lam, fructus lycii, angelica sinensis, paeonia lactiflora pallas, cornus officinalis, salvia miltiorrhiza bunge, peach kernels, carthamus tinctorius and achyranthes bidentata. According to different characteristics of traditional Chinese medicines, the raw materials are washed, diced and preprocessed and then prepared proportionally. The traditional Chinese medicine preparation is prepared through a special method and has the effects of tonifying the kidneys, growing bones, benefiting the liver, tonifying the spleen and promoting blood circulation to remove meridian obstruction. The combining and preparation method of the traditional Chinese medicine preparation is unique, and clinical verification shows that the traditional Chinese medicine preparation has a significant treatment effect, a short treatment period and low price, has no untoward effects or any toxic or side effects and has broad market application prospects.

The invention discloses a traditional Chinese medicine preparation for preventing and treating osteoporosis. The traditional Chinese medicine preparation is prepared from the following crude drugs in parts by weight: 1-10 parts of sea otter, 10-50 parts of epimedium herbs and 10-50 parts of semen cuscutae. Proved by pharmacodynamic study, the traditional Chinese medicine preparation disclosed by the invention can be used for remarkably improving the physiological status of a rat bone with osteoporosis caused by estrogen deficiency, enhancing the strength and toughness of the bone, obviously promoting the bone forming ability of an osteoblast and remarkably inhibiting the bone absorbing ability of an osteoclast so as to have a remarkable effect for preventing and treating postmenopausal osteoporosis. The invention also discloses a preparation method of a traditional Chinese medicine preparation for treating the postmenopausal osteoporosis.

The invention belongs to the field of medicinal preparations, and relates to a lasofoxifene tartrate orally disintegrating tablet for treating postmenopausal osteoporosis and a preparation method thereof. Proper medical auxiliaries are selected according to physicochemical properties of lasofoxifene tartrate, and the orally disintegrating tablet comprises a filling agent, a disintegrating agent, a flavoring agent, a lubricant, a glidant and the like. The medicine can be prepared by granulating and tabletting by a wet method, directly tabletting, or granulating and tabletting by a dry method. The invention aims to provide the lasofoxifene tartrate orally disintegrating tablet with simple preparation process, convenience in administration, quick response to indications, exact curative effect and high bioavailability.

The invention relates to the field of medicines, in particular to application of matrine derivatives in preparation of medicines for preventing or treating postmenopausal osteoporosis. The structural general formula of the matrine derivatives is as shown in formula I. The invention provides a new use for the matrine derivatives, and also provides a new idea for the prevention and treatment of the postmenopausal osteoporosis. The formula I is described in the description.

The invention discloses application of probiotics or outer membrane vesicles thereof to preparing medicines for preventing and treating osteoporosis. The probiotics is an Akk bacterium. The probioticsor the outer membrane vesicles of the probiotics can be used for increasing the bone volume fractions of distal-end cancellous bones of femurs, increasing the numbers of bone trabeculas and loweringthe separation of the bone trabeculas. The probiotics or the outer membrane vesicles of the probiotics can be used for preparing the medicines, food or healthcare products for preventing and treatingpostmenopausal osteoporosis. The application has the advantage that novel, safe and effective biotherapy directions can be provided to treating the osteoporosis and particularly the postmenopausal osteoporosis by the application.

The invention relates to a molecular traditional Chinese medicine sustained-release tablet for resisting bone mass loss and a preparation method thereof. The molecular traditional Chinese medicine sustained-release tablet comprises molecular traditional Chinese medicine ingredients and pharmaceutically allowed auxiliary material ingredients, wherein the molecular traditional Chinese medicine components comprise 1-5 parts of specnuezhenide (ligustrum lucidum), 1-5 parts of wedelolactone (eclipta prostrata), 0.5-3 parts of paeoniflorin (peony), 0.5-3 parts of psoralen (psoralea corylifolia), and 1-5 parts of diosgenin (yam) ]; and the auxiliary material ingredients comprise 10-50 parts of sodium alginate, 1-5 parts of carbomer (934) , 10-30 parts of hydroxypropyl methyl cellulose, 10-40 parts of lactose, and 1-5 parts of magnesium stearate. Based on a theory of Chinese medicine and a theory of sustained-release preparations, Chinese medicine pathological features of postmenopausal osteoporosis, and scientific compatibility, the molecular traditional Chinese medicine sustained-release tablet which is safe and reliable, high in bioavailability and significant in curative effect is developed.

The invention relates to a medicament for treating postmenopausal osteoporosis of women. The medicament is characterized by containing alfacalcidol and alendronate sodium. The alfacalcidol and the alendronate sodium have the same point and the different points on the mechanism of action. By utilizing the alfacalcidol and the alendronate sodium, complementation of the mechanism of action can be realized, the defect of single mechanism is remedied, and treatment to face osteoporosis is better realized.

The invention discloses application of a traditional Chinese medicine composition in preparation of a medicine for treating postmenopausal osteoporosis, and relates to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared by taking raspberries, rhizoma atractylodis macrocephalae, radix paeoniae alba, polygonum multiflorum, jujube kernels, radix angelica sinensis, codonopsis pilosula, morinda officinalis, radix acanthopanacis semticosi, rhizoma dioscoreae, poria cocos, radix rehmanniae preparata, radix puerariae, eucommia ulmoides, mint, rhizoma polygonati, glossy privet fruit, herba epimedii, barbary wolfberry fruit, cornus officinalis, calcium lactate, semen cuscutae, cattle bone powder, rhizoma drynariae and liquorice as raw materials. According to the traditional Chinese medicine composition, the bone mineral density of a postmenopausal osteoporosis patient can be increased, and secondary pain and inflammatory reactions caused by the postmenopausal osteoporosis can be relieved; pharmacological experiments and clinical experiments prove that the traditional Chinese medicine composition has the significant effect for treating the postmenopausal osteoporosis, and therefore the wide medical popularization value is achieved.

The invention provides a traditional Chinese medicine composition for preventing and / or treating postmenopausal osteoporosis. The traditional Chinese medicine composition is composed of the following medicinal raw materials in parts by weight: 28 to 31 parts of fructus psoraleae, 27 to 32 parts of semen cuscutae, 26 to 32 parts of rhizoma drynariae, 24 to 26 parts of wolfberry, 21 to 25 parts of donkey-hide gelatin, 22 to 25 parts of raspberry, 22 to 26 parts of cyperus rotundus, 23 to 25 parts of red sage root, and 22 to 24 parts of achyranthes root. The invention also provides a traditional Chinese medicine preparation containing the traditional Chinese medicine composition. The provided traditional Chinese medicine composition and traditional Chinese medicine preparation have the functions of tonifying the kidney, boosting the essence, strengthening the waist and enhancing the bones, and are especially suitable for women having postmenopausal osteoporosis and symptoms of deficient kidney and insufficient essence. The experiment data shows that compared to other drugs, which have been reported, for treating postmenopausal osteoporosis, the provided traditional Chinese medicine composition has a more prominent functions of tonifying kidney and enhancing bones, and has a better curative effect on postmenopausal osteoporosis.

The invention discloses applications of a small molecular compound Salubrinal in drugs for treating or preventing osteoporosis and osteopenia diseases. Through the utilization of a mouse model of postmenopausal osteoporosis caused by OVX ovariectomy, a mouse model of disuse osteoporosis caused by tail suspension, in vivo and in vitro analysis of primary bone marrow-derived cells and the indicationof cell line-based experimental results, Salubrinal administration can effectively relieve OVX related symptoms, stimulate the differentiation of osteoblasts and inhibit the development of osteoclasts. Through the indication of precise molecular mechanism of the Salubrinal, the Salubrinal can be applied to drugs for treating or preventing osteopenia diseases caused by postmenopausal osteoporosis,disuse osteoporosis and other factors.

The invention belongs to the field of traditional Chinese medicine, and discloses a traditional Chinese medicine composition for treating female postmenopausal osteoporosis and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 10 to 20 parts of eucommia ulmoides, 6 to 12 parts of herba epimedii, 5 to 10 parts of safflower carthamus, 5 to 10 parts of rhizoma corydalis, 5 to 10 parts of radix rehmanniae praeparata, 3 to 10 parts of pericarpium citri reticulatae viride, 3 to 10 parts of glossy privet fruit, 3 to 10 parts of rhizoma anemarrhenae, 3 to 6 parts of Chinese yam, 3 to 6 parts of adenophora stricta and 1 to 12 parts of liquorice. The traditional Chinese medicine composition provided by the invention is prepared from the natural traditional Chinese medicinal materials, is small in toxic and side effects, and simple in manufacturing process, has the efficacy of strengthening tendons and bones, activating blood to promote menstruation, nourishing yin and supplementing blood, invigorating spleen and replenishing Qi, and can be used for effectively treating female postmenopausal osteoporosis.

The invention belongs to the field of traditional Chinese medicine, and discloses a traditional Chinese medicine composition for treating female postmenopausal osteoporosis and a preparing method thereof. The traditional Chinese medicine composition is prepared from, by weight, 10-25 parts of moringa oleifera leaves, 6-15 parts of radix dipsaci, 5-10 parts of codonopsis pilosula, 5-10 parts of rhizoma polygonati, 5-10 parts of radix rehmanniae praeparata, 3-9 parts of caulis spatholobi, 3-9 parts of radix clematidis, 3-9 parts of radix angelicae, 3-6 parts of Chinese yam, 3-6 parts of rhubarb and 1-10 parts of liquorice. The traditional Chinese medicine composition is prepared from natural traditional Chinese medicine, side effect is small, the preparing process is simple, the functions of enriching blood and stopping pain, strengthening tendons and bones, and promoting blood circulation to remove meridian obstruction are realized, and female postmenopausal osteoporosis can be effectively treated.

The invention discloses a medicinal composite containing cornu cervi pantotrichum. The medicinal composite comprises the following components in percentage by weight: 1%-20% of cornu cervi pantotrichum freeze-dried powder, 1%-10% of glucosamine, 1%-20% of collagen, 1%-10% of vitamins B6, 1%-20% of dolomites and 95%-20% of germinated soybean meal, wherein the sum of drugs is 100%; the cornu cervi pantotrichum freeze-dried powder is prepared through the following steps of: freeze-drying fresh cornu cervi pantotrichum, smashing, extracting at 0-4 DEG C by using normal saline, centrifugalizing an extracting solution, and freeze-drying a supernatant into powder. The medicinal composite disclosed by the invention is prepared into a postmenopausal osteoporosis animal model by adopting a ovariotomy method and continuously applied for 12 weeks, is displayed to be used for preventing and treating cancellous bone losing caused due to estrogen reduction through a result and prompted to correct the bone turnover rate enhancement caused due to low estrogen level and improve the coupling unbalance condition of bone absorption and bone formation through a bone metabolism biochemical index and a bone density result, promotes the bone formation and has certain preventing and treating effects on high-turnover type osteoporosis which takes the cancellous bone losing as a main part.